Evidence map›Paper›PMID 42496813›Full record

ReviewCurrent osteoporosis reports2026

The Role of Short-Chain Fatty Acids and Derived Metabolites in Osteoporosis.

Guanghong Qiu, Sihui Xie, Wenjia Luo, Kangping Yang, Jiaqiang Wu, Xianhuan Zhou, Shiqi Li, Yufan Hu, Liang Yang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current osteoporosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guanghong Qiu *Department of Gastroenterological Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Sihui Xie *Department of Gastroenterological Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Wenjia Luo *The Second Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Kangping YangDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1, Minde Road, Donghu District, Nanchang, 330006, China.
Jiaqiang WuDepartment of Gastroenterological Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Xianhuan ZhouDepartment of Gastroenterological Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Shiqi LiThe Second Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Yufan HuAffiliated Rehabilitation Hospital of Nanchang University, Nanchang, 330006, China.
Liang YangDepartment of Gastroenterological Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. ncu_yangliang@163.com.ORCID https://orcid.org/0009-0001-2745-1712

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo investigate the role of short-chain fatty acids (SCFAs) in the pathogenesis of osteoporosis and their potential value as therapeutic targets. RECENT

findingsRecent studies have shown that SCFAs, metabolic products of gut microbiota, play a crucial regulatory role in bone remodeling. SCFAs achieve this by activating G protein-coupled receptors (GPCRs), inhibiting histone deacetylases (HDACs), and regulating signaling pathways involved in bone metabolism. This effectively suppresses osteoclast activity, reduces bone resorption, enhances osteoblast function, and alleviates oxidative stress, thereby promoting bone formation. These findings not only reveal the key mechanisms by which SCFAs maintain bone metabolic homeostasis but also highlight their potential for treating osteoporosis in the elderly and postmenopausal women. Related clinical trials and drug research are currently underway. This review explores the potential value and theoretical basis of targeting SCFAs for the prevention and treatment of osteoporosis, summarizes existing clinical trials and related drug research, and provides new directions for developing future treatment strategies.

Indexed as

Bone RemodelingFatty Acids, VolatileOsteoporosisAnimalsBone ResorptionFemaleGastrointestinal MicrobiomeHistone Deacetylase InhibitorsHumansOsteoblastsOsteoclastsOsteogenesisOxidative StressReceptors, G-Protein-CoupledSignal TransductionFatty Acids, VolatileHistone Deacetylase InhibitorsReceptors, G-Protein-CoupledBone metabolismGut microbiotaOsteoporosisSCFAsTherapy

Identifiers

PMID42496813

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.